[go: up one dir, main page]

WO2000010541A1 - Formulations proteiques atomisees stables - Google Patents

Formulations proteiques atomisees stables Download PDF

Info

Publication number
WO2000010541A1
WO2000010541A1 PCT/US1999/019306 US9919306W WO0010541A1 WO 2000010541 A1 WO2000010541 A1 WO 2000010541A1 US 9919306 W US9919306 W US 9919306W WO 0010541 A1 WO0010541 A1 WO 0010541A1
Authority
WO
WIPO (PCT)
Prior art keywords
spray
particles
dried particles
bioactive agent
phospholipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/019306
Other languages
English (en)
Inventor
David A. Edwards
Jeffrey S. Hrkach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Inhalation Research Inc
Original Assignee
Advanced Inhalation Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Inhalation Research Inc filed Critical Advanced Inhalation Research Inc
Priority to DE69936386T priority Critical patent/DE69936386T2/de
Priority to JP2000565863A priority patent/JP4416325B2/ja
Priority to DK99945175T priority patent/DK1107743T3/da
Priority to EP99945175A priority patent/EP1107743B1/fr
Priority to AU57842/99A priority patent/AU758351B2/en
Priority to CA002341624A priority patent/CA2341624C/fr
Publication of WO2000010541A1 publication Critical patent/WO2000010541A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Definitions

  • Aerosols for the delivery of therapeutic agents to the respiratory tract have been described, for example, Adjei, A. and Garren, J. Pharm. Res., 7: 565-569 (1990); and Zanen, P. and Lamm, J.-W.J. Int. J. Pharm., 114: 111-115 (1995).
  • the respiratory tract encompasses the upper airways, including the oropharynx and larynx, followed by the lower airways, which include the trachea followed by bifurcations into the bronchi and bronchioli.
  • the upper and lower airways are called the conducting airways.
  • the terminal bronchioli then divide into respiratory bronchioli which then lead to the ultimate respiratory zone, the alveoli, or deep lung. Gonda, I.
  • Inhaled aerosols have been used for the treatment of local lung disorders including asthma and cystic fibrosis (Anderson, Am. Rev. Respir. Dis., 140: 1317- 1324 (1989)) and have potential for the systemic delivery of peptides and proteins as well . (PaUon and Plate, Advanced Drug Delivery Reviews, 8: 179-196 (1992)).
  • pulmonary drug delivery strategies present many difficulties for the delivery of macromolecules; these include protein denaturation during aerosolization, excessive loss of inhaled drug in the oropharyngeal cavity (often exceeding 80%), poor control over the site of deposition, lack of reproducibility of therapeutic results owing to variations in breathing patterns, the frequent too-rapid absorption of drug potentially resulting in local toxic effects, and phagocytosis by lung macrophages.
  • Dry powder formulations with large particle size have improved flowability characteristics, such as less aggregation (Visser, J., Powder Technology 58: 1-10 (1989)), easier aerosolization, and potentially less phagocytosis. Rudt, S. and R.H. Muller, J. Controlled Release, 22: 263-272 (1992); Tabata, Y. and Y. Ikada, J. Biomed. Mater. Res., 22: 837-858 (1988). Dry powder aerosols for inhalation therapy are generally produced with mean geometric diameters primarily in the range of less than 5 ⁇ m, typically ranging from 1 to 5 ⁇ m. Ganderton, D., J.
  • the human lungs can remove or rapidly degrade, for example by hydrolysis or hydrolytic cleavage, deposited aerosols over periods ranging from minutes to hours.
  • ciliated epithelia contribute to the "mucociliary escalator" by which particles are swept from the airways toward the mouth.
  • alveolar macrophages are capable of phagocytosing particles soon after their deposition.
  • Controlled release drug delivery to the lung may simplify the way in which many drugs are taken. Gonda, I., Adv. Drug Del. Rev., 5: 1-9 (1990); and Zeng, X., et al, Int. J. Pharm., 124: 149-164 (1995).
  • Pulmonary drug delivery is an attractive alternative to oral, transdermal, and parenteral administration because self-administration is simple, the lungs provide a large mucosal surface for drug absorption, there is no first-pass liver effect of absorbed drugs, and there is reduced enzymatic activity and pH mediated drug degradation compared with the oral route. Relatively high bioavailability of many molecules, including macromolecules, can be achieved via inhalation.
  • Drugs currently administered by inhalation come primarily as liquid aerosol formulations.
  • many drugs and excipients especially proteins, peptides (Liu, R., et al. , Biotechnol Bioeng, 37: 177-184 (1991)), and biodegradable carriers such as poly(lactide-co-glycolides) (PLGA)
  • PLGA poly(lactide-co-glycolides)
  • PLGA poly(lactide-co-glycolides)
  • protein denaturation can occur during aerosolization with liquid formulations. Mumenthaler, M., et al, Pharm. Res., 11: 12-20 (1994).
  • DPF's dry powder formulations
  • powders of ultrafine particulates usually have poor flowability and aerosolization properties, leading to relatively low respirable fractions of aerosol, which are the fractions of inhaled aerosol that escape deposition in the mouth and throat.
  • Particles suitable for delivery to the respiratory system of a patient can be prepared by spray drying from aqueous solutions.
  • protein particles which are prepared by spray drying from aqueous solutions tend to be hygroscopic and susceptible to lose their activity at even modest humidity levels.
  • Spray drying in the presence of polysorbate-20 surfactant has been shown to reduce the aggregation of recombinant growth hormone during spray drying.
  • solvents including water and methanol or water and ethanol have been employed to spray dry hollow albumin microcapsules. Neither technique, however, has resulted in both, improved protein stability and reduced protein hygroscopicity.
  • the invention relates to methods of producing spray-dried particles, also referred to herein as particles, which have improved bioactive agent stability.
  • the method includes combining a biologically active (bioactive) agent, a phospholipid and an organic-aqueous co- solvent to form a mixture which is spray-dried to produce spray-dried particles having improved bioactive agent stability.
  • the method includes combining a bioactive agent, a phospholipid and an organic solvent to form a mixture which is spray-dried to produce particles having improved bioactive agent stability.
  • the bioactive agent is a therapeutic, prophylactic or a diagnostic agent.
  • the bioactive agent includes peptides. In another embodiment, the bioactive agent includes proteins. In a further embodiment, the bioactive agent includes biologically active or bioactive macromolecules other than peptides or proteins. In still another embodiment of the invention, the agent includes any combination of peptides, proteins and/or other biologically active macromolecules.
  • the phospholipid is present in the spray-dried particle in an amount of at least 1 weight %.
  • the phospholipid is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols and combinations thereof.
  • the spray dried particles have a tap density less than 0.4 g/cm 3 .
  • the invention also relates to a method including administering an effective amount of the spray-dried particles obtained by the methods of the invention to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis.
  • the spray dried particles can be used for enhanced delivery of a therapeutic, prophylactic or diagnostic agent to the airways or the alveolar region of the lung.
  • the particles may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of a wide variety of therapeutic agents.
  • the particles can be used to form a composition that includes the particles and a pharmaceutically acceptable carrier for administration to a patient, preferably for administration via inhalation.
  • the spray-dried particles can themselves be used as carriers for the delivery of a therapeutic, prophylactic or diagnostic agent to the pulmonary system.
  • a therapeutic, prophylactic or diagnostic agent can be added onto the spray-dried carrier particles for delivery to the pulmonary system.
  • Small-sized therapeutic, prophylactic or diagnostic agents such as, for example, agents having a particle size in the nanometer range, can be carried by the spray-dried carrier particles and delivered to the pulmonary system.
  • the invention By providing a method for producing spray-dried particles which have increased protein stability, the invention has numerous advantages. In addition, it provides a method for producing aerodynamically light particles suitable for delivery to the respiratory system.
  • bioactive agent includes peptides and proteins. Proteins are defined herein as having about 100 amino acid residues or more, while peptides are defined herein as having less than about 100 amino acid residues.
  • bioactive agent also includes bioactive macromolecules other than peptides or proteins.
  • bioactive macromolecules include, but are not limited to: polysaccharides and other sugars, lipids, DNA, RNA, nucleic acid sequences, genes, antisense molecules, antigens and others.
  • the bioactive agent can be a therapeutic, prophylactic or diagnostic agent.
  • preferred biologically active agents include but are not limited to: insulin, erythroprotein, interferons, colony stimulating factors, such as, granulocyte colony stimulating factor, growth hormones, such as, for example, human growth hormone, LHRH analogs, LHRH antagonists, tissue plasminogen activator, somatostatin analog, r Factor VIII, r Factor IX, calcitonin, abciximab, dornase alfa, polysaccharides, AG337, bone inducing protein, bone morphogenic protein, brain derived growth factor, gastrin 17 immunogen, interleukins, such as, for example, IL- 2, PEF superoxide, infliximab, permeability increasing protein-21, platelet derived growth factor, stem cell factor, Thyrogen R and somatomedin C.
  • colony stimulating factors such as, granulocyte colony stimulating factor
  • growth hormones such as, for example, human growth hormone, LHRH analogs, LHRH antagonist
  • the term stability generally is related to maintaining the integrity or to minimizing the denaturation, aggregation or unfolding of a biologically active agent such as a protein, peptide or another bioactive macromolecule after being exposed to conditions known to negatively affect its stability.
  • improved stability generally means that, under conditions known to result in degradation, denaturation, aggregation or unfolding, the bioactive agent maintains greater stability compared to control particles subjected to the same conditions.
  • Control particles can be, for example, commercially available particles or powders which include the bioactive agent.
  • control particles can include lyophilized bulk proteins or lyophilized sugars.
  • Control particles can also be particles obtained by methods other than the methods of the invention.
  • control particles can include particles that are spray-dried from aqueous solutions or particles that do not include a phospholipid.
  • Protein degradation for example, is often facilitated by water.
  • Improved protein stability can be demonstrated in terms of improved retention of protein integrity under storage conditions at specified moisture levels.
  • spray- dried particles having improved protein stability are particles which undergo less degradation, denaturation, aggregation and/or unfolding, relative to protein formulations spray-dried from aqueous solutions, or spray-dried from mixtures that do not include a phospholipid, after storage for six weeks at about 25 °C (e.g. +/- 2°C) and about 60% (e.g. +/- 5%) relative humidity.
  • spray-dried particles having improved protein stability are particles which, after storage for six weeks at about 40°C (e.g. +/- 2°C) and about 75% (e.g. +/- 5%) relative humidity, retain greater protein stability (or undergo less degradation, denaturation, aggregation and/or unfolding) compared to protein formulations spray-dried from aqueous solutions or spray-dried from mixtures that do not include a phospholipid.
  • the spray-dried particles retain at least about 70%, preferably at least about 80% protein integrity, when stored at about 25 °C and about 60% relative humidity conditions for six weeks.
  • the spray-dried particles retain at least about 50%, preferably at least about 60% protein integrity when stored at about 40°C and about 75% relative humidity conditions for six weeks.
  • Bioactive agent stability or integrity can be measured by techniques such as those known in the art.
  • protein stability can be measured by size exclusion high performance liquid chromatography (SEC HPLC).
  • SEC HPLC size exclusion high performance liquid chromatography
  • Other suitable techniques for detecting bioactive agent stability, aggregation or degradation include, but are not limited to: reverse phase high performance liquid chromatography (RP HPLC); sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE); enzyme-linked immunoadsorbent assay (ELISA) and radioimmunoassay (RIA).
  • RP HPLC reverse phase high performance liquid chromatography
  • SDS PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
  • ELISA enzyme-linked immunoadsorbent assay
  • RIA radioimmunoassay
  • the method for producing spray-dried particles having improved bioactive agent stability includes combining a bioactve agent, such as, for example, the agents described above,
  • Co-solvents include an aqueous solvent and an organic solvent.
  • Suitable organic solvents that can be employed include but are not limited to alcohols such as, for example, ethanol, methanol, propanol, isopropanol and butanols.
  • Other organic solvents include but are not limited to perfluorocarbons, dichloromethane, chloroform, ether, ethyl acetate, methyl tert-butyl ether and others.
  • Aqueous solvents include water and buffered solutions.
  • the organic solvent is ethanol.
  • the amount of organic solvent can be present in the co-solvent in an amount ranging from about 50 to about 90% by volume.
  • the organic solvent is present in the co-solvent in an amount ranging from about 60 to about 85% by volume.
  • the method for producing spray-dried particles having improved bioactive agent stability includes combining a bioactive agent, such as, for example, the agents described above, with a phospholipid and an organic solvent to form a mixture.
  • the organic solvent includes but is not limited to the organic solvents described above.
  • the phospholipid also referred to herein as phosphoglyceride, is a phospholipid endogenous to the lung. Such a phospholipid is particularly advantageous in preparing spray-dried particles suitable for delivery to the respiratory system of a patient.
  • the phospholipid is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols and combinations thereof.
  • Specific examples of phospholipids include but are not limited to phosphatidylcholines dipalmitoyl phosphatidylcholine (DPPC), dipalmitoyl phosphatidylethanolamine (DPPE), distearoyl phosphatidylcholine (DSPC), dipalmitoyl phosphatidyl glycerol (DPPG) or any combinations thereof.
  • the mixture can have a neutral, acidic or alkaline pH.
  • a pH buffer can be added to the solvent or co-solvent or to the formed mixture.
  • the pH can range from about 3 to about 10.
  • the mixture obtained by combining the bioactive agent with the phospholipid and the co-solvent is spray-dried.
  • Suitable spray-drying techniques are described, for example, by K. Masters in "Spray Drying Handbook", John Wiley & Sons, New York, 1984.
  • heat from a hot gas such as heated air or nitrogen is used to evaporate the solvent from droplets formed by atomizing a continuous liquid feed.
  • a rotary atomizer is employed.
  • suitable spray driers using rotary atomization include Niro spray drier Mobile Minor.
  • the phospholipid is present in the spray-dried particles in an amount of at least about 1 weight %. In another embodiment, the phospholipid is present in the particles in an amount ranging from about 1% to about 99%, preferably from about 10% to about 70% by weight.
  • the amount of phospholipid to be included in the particles can be determined experimentally by determining the amount of phospholipid which, when included in the spray-dried particles, results in improved stability, measured by means such as, but not limited to, those described above.
  • the bioactive agent can be present in the spray-dried particles of the invention in an amount ranging from about 1 to about 99 weight %, preferably from about 30 to about 90 weight %.
  • the spray-dried particles include a protein, which is present in the particles in an amount ranging from about 1 to about 99 weight %, preferably in an amount ranging from about 30 to about 90 weight %.
  • the improved stability is at least in part the result of a lowered tendency of the protein to be situated at the air- water interface or air-co-solvent interface of the droplet.
  • the phospholipid is believed to compete with the protein for the air-droplet interface, thereby protecting the protein.
  • the presence of the phospholipid also renders the spray-dried particles less prone to degradation owing to exposure to high humidity conditions during storage.
  • the spray-dried particles consist of bioactive agent and phospholipid.
  • the spray-dried particles include only the bioactive agent, such as, for example, the proteins, peptides or bioactive macromolecule or any mixtures thereof described above and a phospholipid, such as, for example, the phospholipids described above.
  • the bioactive agent can be in the form of a complex between the charged agent and a molecule of opposite charge. This can be the case for many proteins.
  • the molecule of opposite charge can be a charged lipid or an oppositely charged protein.
  • the molecule of the opposite charge can also be a cation such as Ca ++ or Zn ++ .
  • agent to be delivered is negatively charged (such as insulin), protamine or other positively charged molecules can be added to provide a lipophilic complex which results in the sustained release of the negatively charged agent.
  • Negatively charged molecules can be used to render insoluble positively charged agents.
  • the particles consist essentially of bioactive agent and phospholipd.
  • the spray-dried particles can further include small or trace amounts of residual solvent or co-solvent, impurities, substances which control the pH, or other materials in small or trace amounts. Ranges for impurity levels and for residual solvent levels are generally well established in the industry and known to those skilled in the art. Amounts of pH buffers that can be added to the solvent, co-solvent or mixture are also known in the art.
  • the spray-dried particles can include materials in addition to the compounds discussed above.
  • the spray dried particles can include excipients such as, for example, a sugar, such as lactose, amino acids, surfactants or buffer salts, polysaccharides, cyclodextrins and others.
  • the spray-dried particles of the invention can also include one or more compounds employed in controlled or sustained release formulations.
  • the spray-dried particles can include a biocompatible, and preferably biodegradable polymer, copolymer, or blend.
  • Preferred polymers are those which are capable of forming aerodynamically light particles having a tap density less than about 0.4 g/cm 3 , a mean diameter between about 5 ⁇ m and about 30 ⁇ m and an aerodynamic diameter between about one and about five microns, preferably between one and three microns.
  • the polymers may be tailored to optimize different characteristics of the particle including: i) interactions between the bioactive agent to be delivered and the polymer to provide stabilization of the bioactive agent and retention of activity upon delivery; ii) rate of polymer degradation and, thereby, rate of drug release profiles; iii) surface characteristics and targeting capabilities via chemical modification; and iv) particle porosity.
  • polyanhydrides such as poly[(p-carboxyphenoxy)-hexane anhydride] (PCPH) may be used.
  • PCPH poly[(p-carboxyphenoxy)-hexane anhydride]
  • Suitable biodegradable polyanhydrides are described in U.S. Patent No. 4,857,311.
  • bulk eroding polymers such as those based on polyesters including poly(hydroxy acids) can be used.
  • polyglycolic acid (PGA), polylactic acid (PLA), or copolymers thereof may be used to form the particles.
  • the polyester may also have a charged or functionalizable group, such as an amino acid.
  • particles with controlled release properties can be formed of poly(D,L-lactic acid) and/or poly (D,L-lactic-co-gly colic acid) ("PLGA”) which incorporate a surfactant such as DPPC.
  • Still other polymers include polyamides, polycarbonates, polyalkylenes such as polyethylene, polypropylene, poly(ethylene glycol), poly(ethylene oxide), poly(ethylene terephthalate), poly vinyl compounds such as polyvinyl alcohols, poly vinyl ethers, and polyvinyl esters, polymers of acrylic and methacrylic acids, celluloses and other polysaccharides, and peptides or proteins, or copolymers or blends thereof. Polymers may be selected with or modified to have the appropriate stability and degradation rates in vivo for different controlled drug delivery applications.
  • the particles include functionalized polyester graft copolymers, as described in Hrkach et al, Macromolecules, 28: 4736-4739 (1995); and Hrkach et al, "Poly(L-Lactic acid-co-amino acid) Graft Copolymers: A Class of Functional Biodegradable Biomaterials" in Hydrogels and Biodegradable Polymers or Bioapplications, ACS Symposium Series No. 627, Raphael M. Ottenbrite et al, Eds., American Chemical Society, Chapter 8, pp. 93-101, 1996.
  • Materials other than biodegradable polymers can be included in the spray- dried particles of the invention. Suitable materials include various non- biodegradable polymers and various excipients.
  • the spray-dried particles of the invention can also include surfactants such as, for example, hexadecanol; fatty alcohols such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid, such as palmitic acid or oleic acid; glycocholate; surfactin; a poloxomer; a sorbitan fatty acid ester such as sorbitan trioleate (Span 85); tyloxapol and a phospholipid.
  • surfactant refers to any compound which preferentially absorbs to an interface between two immiscible phases, such as the interface between water and an organic polymer solution, a water/air interface or organic solvent/air interface.
  • Surfactants generally possess a hydrophilic moiety and a lipophilic moiety, such that, upon absorbing to microparticles, they tend to present moieties to the external environment that do not attract similarly-coated particles, thus reducing particle agglomeration. Surfactants may also promote absorption of a therapeutic or diagnostic agent and increase bioavailability of the agent.
  • a particle "incorporating a surfactant” refers to a particle with a surfactant on at least the surface of the particle.
  • the surfactant may be incorporated throughout the particle and on the surface during particle formation, or may be coated on the particle after particle formation.
  • the surfactant can be coated on the particle surface by adsorption, ionic or covalent attachment, or physically "entrapped” by the surrounding matrix.
  • the surfactant can be, for example, incorporated into controlled release particles, such as polymeric microspheres.
  • the spray-dried particles of the invention can further include a therapeutic, prophylactic or diagnostic compound or drug other than the bioactive agent described above.
  • therapeutic, prophylactic or diagnostic compounds or drugs include, but are not limited to drugs for the treatment or prophylaxis of asthma, enthesima, cystic fibrosis or for systemic treatment.
  • Antiviral, antibacterial or antifungal drugs can be also included as can be diagnostic or prophylactic agents such as known to in the art.
  • suitable therapeutic, prophylactic or diagnostic drugs or compounds, other than the bioactive agent described above, which can be included in the particles can be found in U.S. Patent No. 5,855,913, to Hanes et al, issued January 5, 1999, the contents of which are incorporated herein by reference in their entirety.
  • the spray-dried particles have a tap density less than about 0.4 g/cm 3 . In another embodiment, the spray-dried particles have a tap density less than about 0.1 g/cm 3 . In yet another embodiment, the spray-dried particles have a tap density less than about 0.05 g/cm 3 .
  • the phrase "aerodynamically light particles” refers to particles having a tap density less than about 0.4 g/cm 3 .
  • the tap density of particles of a dry powder may be obtained using a GeoPycTM instrument (Micrometrics Instrument Corp., Norcross, GA 30093). A Dual Platform Microprocessor Controlled Tap Density Tester (Vankel, NC) can also be used.
  • Tap density is a standard measure of the envelope mass density.
  • the envelope mass density of an isotropic particle is defined as the mass of the particle divided by the minimum sphere envelope volume within which it can be enclosed.
  • Features which can contribute to low tap density include irregular surface texture and porous structure.
  • the preferred median diameter for aerodynamically light particles for inhalation therapy is at least about 5 microns ( ⁇ m), for example between about 5 and about 30 ⁇ m.
  • the spray-dried particles have a median geometric diameter of between about 5 ⁇ m and about 30 ⁇ m. Terms such as median diameter, mass median diameter (MMD), mass median geometric diameter (MMGD) and mass median envelope diameter (MMED) are herein used interchangeably.
  • the term diameter in contrast with the term “aerodynamic diameter”, refers herein to mass or geometric diameter.
  • the terms “aerodynamic diameter” and “mass median aerodynamic diameter” (MMAD) are used herein interchangeably.
  • the mass median aerodynamic diameter is between about 1 ⁇ m and about 5 ⁇ m. In another embodiment of the invention, the mass median aerodynamic diameter is between about 1 ⁇ m and about 3 ⁇ m. In another embodiment, the mass median aerodynamic diameter is between about 3 ⁇ m and about 5 ⁇ m.
  • the mass median diameter of the spray-dried particles can be measured using an electrical zone sensing instrument such as Coulter Multisizer He (Coulter, Miami, FL) or a laser diffraction instrument (for example a Helos instrument manufactured by Sympatec, Princeton, NJ).
  • the diameter of particles in a sample will range depending upon factors such as particle composition and methods of synthesis.
  • the distribution of size of particles in a sample can be selected to permit optimal dep sition within targeted sites within the respiratory tract.
  • Aerodynamically light particles may be fabricated or separated, for example by filtration or centrifugation, to provide a particle sample with a preselected size distribution. For example, greater than 30%, 50%, 70%, or 80% of the particles in a sample can have a diameter within a selected range of at least about 5 ⁇ m. The selected range within which a certain percentage of the particles must fall may be for example, between about 5 and about 30 ⁇ m, or optionally between about 5 and about 15 ⁇ m. In one preferred embodiment, at least a portion of the particles have a diameter between about 9 and about 11 ⁇ m.
  • the particle sample also can be fabricated wherein at least about 90%, or optionally about 95% or about 99%, have a diameter within the selected range. The presence of the higher proportion of the aerodynamically light, larger diameter particles in the particle sample enhances the delivery of therapeutic or diagnostic agents incorporated therein to the deep lung. Large diameter particles generally mean particles having a median geometric diameter of at least about 5 ⁇ m.
  • Aerodynamically light particles with a tap density less than about 0.4 g/cm 3 , median diameters of at least about 5 ⁇ m, and an aerodynamic diameter of between about one and about five microns, preferably between about one and about three microns, are more capable of escaping inertial and gravitational deposition in the oropharyngeal region, and are targeted to the airways or the deep lung.
  • the use of larger, more porous particles is advantageous since they are able to aerosolize more efficiently than smaller, denser aerosol particles such as those currently used for inhalation therapies.
  • the larger aerodynamically light particles preferably having a median diameter of at least about 5 ⁇ m, also can potentially more successfully avoid phagocytic engulfment by alveolar macrophages and clearance from the lungs, due to size exclusion of the particles from the phagocytes' cytosolic space. Phagocytosis of particles by alveolar macrophages diminishes precipitously as particle diameter increases beyond about 3 ⁇ m.
  • the particle envelope volume is approximately equivalent to the volume of cytosolic space required within a macrophage for complete particle phagocytosis.
  • Aerodynamically light particles thus are capable of a longer term release of an encapsulated agent in the lungs.
  • aerodynamically light biodegradable particles can deposit in the lungs, and subsequently undergo slow degradation and drug release, without the majority of the particles being phagocytosed by alveolar macrophages.
  • the drug can be delivered relatively slowly into the alveolar fluid, and at a controlled rate into the blood stream, minimizing possible toxic responses of exposed cells to an excessively high concentration of the drug.
  • the aerodynamically light particles thus are highly suitable for inhalation therapies, particularly in controlled release applications.
  • the particles may be fabricated with the appropriate material, surface roughness, diameter and tap density for localized delivery to selected regions of the respiratory tract such as the deep lung or upper airways.
  • higher density or larger particles may be used for upper airway delivery, or a mixture of varying sized particles in a sample, provided with the same or different therapeutic agent may be administered to target different regions of the lung in one administration.
  • Particles having an aerodynamic diameter in the range from about 3 to about 5 ⁇ m are preferred for delivery to the central and upper airways.
  • Particles having an aerodynamic diameter in the range from about 1 to about 3 ⁇ m are preferred for delivery to the deep lung.
  • Inertial impaction and gravitational settling of aerosols are predominant deposition mechanisms in the airways and acini of the lungs during normal breathing conditions. Edwards, D.A., J. Aerosol Sci., 26: 293-317 (1995). The importance of both deposition mechanisms increases in proportion to the mass of aerosols and not to particle (or envelope) volume. Since the site of aerosol deposition in the lungs is determined by the mass of the aerosol (at least for particles of mean aerodynamic diameter greater than approximately 1 ⁇ m), diminishing the tap density by increasing particle surface irregularities and particle porosity permits the delivery of larger particle envelope volumes into the lungs, all other physical parameters being equal. The low tap density particles have a small aerodynamic diameter in comparison to the actual envelope sphere diameter.
  • the aerodynamic diameter, c aer is related to the envelope sphere diameter, d (Gonda, I., "Physico-chemical principles in aerosol delivery,” in Topics in Pharmaceutical Sciences 1991 (eds. D.J.A. Crommelin and K.K. Midha), pp. 95-117, Stuttgart: Medpharm Scientific Publishers, 1992)), by the formula:
  • d is always greater than 3 ⁇ m.
  • p 0.1 g/cm 3
  • the increased particle size diminishes interparticle adhesion forces.
  • large particle size increases efficiency of aerosolization to the deep lung for particles of low envelope mass density, in addition to contributing to lower phagocytic losses.
  • the spray-dried particles have a tap density less than about 0.4 g/cm 3 and a median diameter between about 5 ⁇ m and about 30 ⁇ m, which in combination yield an aerodynamic diameter of between about 1 and about 5 ⁇ m, preferably between about 1 and about 3 ⁇ m.
  • the aerodyanamic diameter is calculated to provide for maximum deposition within the lungs, previously achieved by the use of very small particles of less than five microns in diameter, preferably between one and three microns, which are then subject to phagocytosis. Selection of particles which have a larger diameter, but which are sufficiently light (hence the characterization "aerodynamically light"), results in an equivalent delivery to the lungs, but the larger size particles are not phagocytosed. Improved delivery can be obtained by using particles with a rough or uneven surface relative to those with a smooth surface.
  • the particles have a mass density of less than about 0.4 g/cm 3 and a mean diameter of between about 5 ⁇ m and about 30 ⁇ m.
  • Mass density and the relationship between mass density, mean diameter and aerodynamic diameter are discussed in U. S. Application No. 08/655,570, filed on May 24, 1996, which is incorporated herein by reference in its entirety.
  • the aerodynamic diameter of particles having a mass density less than about 0.4 g/cm 3 and a mean diameter of between about 5 ⁇ m and about 30 ⁇ m is between about 1 ⁇ m and about 5 ⁇ m.
  • the spray-dried particles can be used for controlled systemic or local delivery of therapeutic or diagnostic agents to the respiratory tract via aerosolization.
  • Administration of the particles to the lung by aerosolization permits deep lung delivery of relatively large diameter therapeutic aerosols, for example, greater than about 5 ⁇ m in median diameter.
  • the particles can be fabricated with a rough surface texture to reduce particle agglomeration and improve flowability of the powder.
  • the spray-dried particles have improved aerosolization properties.
  • the spray-dried particle can be fabricated with features which enhance aerosolization via dry powder inhaler devices, and lead to lower deposition in the mouth, throat and inhaler device. Aerosol dosage, formulations and delivery systems may be selected for a particular therapeutic application, as described, for example, in Gonda, I.
  • the greater efficiency of aerosolization by the particles disclosed herein relative to particles that do not include a surfactant or a charged complex of a therapeutic agent permits more of a therapeutic agent to be delivered.
  • the use of biodegradable polymers permits controlled release in the lungs and long-time local action or systemic bioavailability. Denaturation of macromolecular drugs can be minimized during aerosolization since macromolecules can be contained and protected within a polymeric shell. Coencapsulation of peptides with peptidase- inhibitors can minimize peptide enzymatic degradation. Pulmonary delivery advantageously can reduce or eliminate the need for injection. For example, the requirement for daily insulin injections can be avoided.
  • the invention is also related to a method for delivery to the pulmonary system.
  • the method comprises administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of the spray dried particles obtained by the methods of the invention.
  • Porous or aerodynamically light particles having a geometric size (or mean diameter) in the range of about 5 to about30 micrometers, and tap density less than about 0.4 g/cm 3 , such that they possess an aerodynamic diameter of about 1 to about 3 ⁇ m, have been shown to display ideal properties for delivery to the deep lung. Larger aerodynamic diameters, preferably ranging, for example from about 3 to about 5 ⁇ m are preferred, however, for delivery to the central and upper airways.
  • the particles have a tap density of less than about 0.4 g/cm 3 and a mean diameter of between about 5 ⁇ m and about 30 ⁇ m.
  • the non-polymeric particles have a mass density of less than about 0.4 g/cm 3 and a mean diameter of between about 5 ⁇ m and about 30 ⁇ m.
  • the particles have an aerodynamic diameter between about one and about five microns.
  • the particles have an aerodynamic diameter between about one and about three microns.
  • the particles have an aerodynamic diameter between about three and about five microns.
  • particles can be delivered from an inhaler device, such as, but not limited to a metered-dose-inhaler (MDI), dry-powder inhaler (DPI) nebulizer or by instillation.
  • MDI metered-dose-inhaler
  • DPI dry-powder inhaler
  • a DPI is described in U.S. Patent No. 4,069,819 issued to Valentini, et al. on August 5, 1976.
  • IgG was obtained from Sigma, St. Louis, MO .
  • the DNA sequence of hGH is described in U.S. patent No, 4,898,830 issued on February 6, 1990 to Goeddel et al.
  • DPPC was obtained from Avanti (Alabaster, ALA) or Sigma.
  • Spray Drying A Mobile Minor spray-drier from Niro (Denmark) was used.
  • the hot gas was dehumidified air or nitrogen .
  • the gas temperature ranged from about 80 to about 150°C.
  • Microsphere morphology was observed by scanning electron microscopy (SEM) using a Stereoscan 250 MK3 microscope from Cambridge Instruments (Cambridge, MA) at 15 kV. Microspheres were freeze-dried, mounted on metal stubs with double-sided tape, and coated with gold prior to observation. Particle Density Analysis
  • IgG particles were prepared to demonstrate that particles suitable for inhalation, with theoretical aerodynamic diameter between 1 and 3 microns, could be prepared by spray drying a protein with DPPC in a water/ethanol cosolvent mixture. A 70/30 ethanol/water co-solvent was employed. The solute concentration (combined IgG and DPPC) was 0.1% w/v. The pH of the water varied from 3-5.7. The spray drying parameters were inlet temperature (110°C), atomizer spin rate (1-2 bar), feed rate of 40 mL/min, and outlet temperature near 50 °C. 40/60 IgG/DPPC and 50/50 IgG/DPPC particles were prepared.
  • the tap densities ranged from 0.02 to 0.2 g/cm 3 with mean geometric diameters near 7 microns. This gave aerodynamic diameters in the range of 1-3 microns, ideal for inhalation. SDS PAGE analysis showed no difference between starting IgG material and spray dried IgG particle indicating no aggregates or degradation.
  • Human growth hormone is one example of a protein susceptible to denaturation during spray drying from an aqueous solution. hGH was spray-dried in an aqueous/ethanol co-solvent mixture with DPPC.
  • a 70/30 ethanol/aqueous co-solvent (vol/vol) and solute concentrations (combined hGH and DPPC) of 0.1% w/v were used.
  • the pH was 7.4 (NaPO 4 buffer).
  • the spray drying parameters were as described above.
  • 60/40 hGH/DPPC and 80/20 hGH/DPPC particles were prepared.
  • the tap densities ranged from 0.02 to 0.04 g/cc with mean geometric diameters of 7-8 microns. This gave aerodynamic diameters in the range of 1-3 microns, ideal for inhalation.
  • the 60% and 80% hGH spray dried particles were analyzed by HPLC to detect instabilities (e.g. aggregation, deamidation).
  • the spray dried particles described above were compared to hGH particles that were spray dried without the presence of DPPC and an organic co-solvent. The analysis showed a reduction of aggregates from 23% to less than 2%, and no detectable deamidation.
  • the stability of hGH was measured by SEC-HPLC which shows the amount of monomer (the active form) and higher molecular weight aggregates.
  • Table 1 presents the SEC-HPLC data demonstrating the better stability of the hGH spray- dried particles (60% hGH and 40% DPPC) versus bulk hGH powder.

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Glanulating (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des particules séchées par atomisation présentant une amélioration de la stabilité des protéines et qui sont produites par atomisation d'un mélange constitué d'une protéine, d'un phospholipide et d'un co-solvant eau/solvant organique. Des particules séchées par atomisation et qui contiennent au moins 1 % en poids de phospholipide présentent une densité après tassement inférieure à 0,4 g/cm3. Les particules peuvent être introduites dans le système pulmonaire d'un patient.
PCT/US1999/019306 1998-08-25 1999-08-25 Formulations proteiques atomisees stables Ceased WO2000010541A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE69936386T DE69936386T2 (de) 1998-08-25 1999-08-25 Sprühgetrocknete proteinformulierungen
JP2000565863A JP4416325B2 (ja) 1998-08-25 1999-08-25 安定な噴霧乾燥タンパク質製剤
DK99945175T DK1107743T3 (da) 1998-08-25 1999-08-25 Stabile, spraytörrede proteinformuleringer
EP99945175A EP1107743B1 (fr) 1998-08-25 1999-08-25 Formulations proteiques atomisees stables
AU57842/99A AU758351B2 (en) 1998-08-25 1999-08-25 Stable spray-dried protein formulations
CA002341624A CA2341624C (fr) 1998-08-25 1999-08-25 Formulations proteiques atomisees stables

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9779698P 1998-08-25 1998-08-25
US60/097,796 1998-08-25

Publications (1)

Publication Number Publication Date
WO2000010541A1 true WO2000010541A1 (fr) 2000-03-02

Family

ID=22265177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019306 Ceased WO2000010541A1 (fr) 1998-08-25 1999-08-25 Formulations proteiques atomisees stables

Country Status (11)

Country Link
EP (1) EP1107743B1 (fr)
JP (1) JP4416325B2 (fr)
AT (1) ATE365547T1 (fr)
AU (1) AU758351B2 (fr)
CA (1) CA2341624C (fr)
CY (1) CY1107488T1 (fr)
DE (1) DE69936386T2 (fr)
DK (1) DK1107743T3 (fr)
ES (1) ES2289823T3 (fr)
PT (1) PT1107743E (fr)
WO (1) WO2000010541A1 (fr)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013891A3 (fr) * 1999-08-25 2001-07-26 Advanced Inhalation Res Inc Modulation de liberation a partir de formulations seches en poudre
US6315983B1 (en) 1996-01-24 2001-11-13 Byk Gulden Lomberg Chemische Fabrik Gmbh Process for the production of powdered pulmonary surfactant preparations
JP2002179589A (ja) * 2000-10-02 2002-06-26 Jcr Pharmaceuticals Co Ltd 生理活性ペプチド含有粉末
WO2001095874A3 (fr) * 2000-06-09 2003-01-16 Advanced Inhalation Res Inc Distribution hautement efficace d'une grande quantite d'aerosol therapeutique
WO2003015756A1 (fr) * 2001-08-17 2003-02-27 Upperton Limited Production de microparticules
US6569406B2 (en) 2000-08-07 2003-05-27 Nektar Therapeutics Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US6630121B1 (en) 1999-06-09 2003-10-07 The Regents Of The University Of Colorado Supercritical fluid-assisted nebulization and bubble drying
WO2002094283A3 (fr) * 2001-05-21 2003-11-27 Britannia Pharmaceuticals Ltd Utilisation de phospholipides dans le traitement de maladie degenerative du poumon et pour ameliorer l'administration de medicaments
WO2003080028A3 (fr) * 2002-03-20 2004-01-22 Advanced Inhalation Res Inc Procede et appareil de production de particules seches
WO2004054556A1 (fr) * 2002-12-13 2004-07-01 Adagit Particules pharmaceutiques poreuses
WO2005020953A1 (fr) * 2003-08-22 2005-03-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Poudres amorphes sechees par atomisation presentant une faible humidite residuelle et une bonne stabilite au stockage
WO2005000267A3 (fr) * 2003-05-28 2005-03-10 Nektar Therapeutics Produit pharmaceutique formule comprenant un principe actif insoluble dans l'eau
JP2005511629A (ja) * 2001-11-20 2005-04-28 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続作用生成物送達用組成物
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
AU2003218306B2 (en) * 2002-03-20 2006-09-14 Advanced Inhalation Research, Inc. Method for administration of growth hormone via pulmonary delivery
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US7306787B2 (en) 1997-09-29 2007-12-11 Nektar Therapeutics Engineered particles and methods of use
CN100365039C (zh) * 2003-01-31 2008-01-30 日本瑞翁株式会社 可聚合组合物、热塑性树脂组合物、交联树脂以及交联树脂复合材料
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
WO2011065600A1 (fr) * 2009-11-25 2011-06-03 Gcbio Corp. Utilisation d'une formulation inhalable en poudre comprenant une hormone de croissance pour prevenir ou traiter les maladies induites par l'hypofonctionnement des recepteurs nmda
EP1303259B1 (fr) * 2000-05-23 2013-03-20 Ethypharm Microspheres a liberation prolongee pour administration injectable et procede de preparation
WO2013114371A1 (fr) 2012-02-01 2013-08-08 Protalix Ltd. Formulation en poudre sèche de dnase i
US8710001B2 (en) 2006-07-31 2014-04-29 Novo Nordisk A/S PEGylated, extended insulins
WO2014121137A2 (fr) 2013-02-01 2014-08-07 Glialogix, Inc. Compositions et méthodes utilisables en vue du traitement de maladies neurodégénératives et autres
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US8889180B2 (en) 2001-04-25 2014-11-18 Western University Of Health Sciences Coated drug delivery formulations
US8936813B2 (en) 2001-11-01 2015-01-20 Novartis Ag Spray drying methods and related compositions
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
WO2016057693A1 (fr) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour administration par inhalation d'oligonucléotide conjugué
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US9688737B2 (en) 2008-03-18 2017-06-27 Novo Nordisk A/S Protease stabilized acylated insulin analogues
US9700529B2 (en) 2002-05-03 2017-07-11 Nektar Therapeutics Particulate materials
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
WO2018075865A1 (fr) 2016-10-21 2018-04-26 Glialogix, Inc. Compositions de traitement de maladies neurodégénératives
EP3346987A1 (fr) * 2015-09-09 2018-07-18 Novartis AG Administration ciblée de formulations séchées par pulvérisation aux poumons
US10265385B2 (en) 2016-12-16 2019-04-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
WO2020223237A1 (fr) 2019-04-29 2020-11-05 Insmed Incorporated Compositions de poudre sèche de promédicaments de tréprostinil et méthodes d'utilisation de celles-ci
WO2023150747A1 (fr) 2022-02-07 2023-08-10 Insmed Incorporated Compositions de poudre sèche de bédaquiline et de sels et leurs méthodes d'utilisation
US12478640B2 (en) 2012-03-07 2025-11-25 Beyond Air Ltd Inhalation of nitric oxide for treating respiratory diseases

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4707937B2 (ja) * 2003-02-28 2011-06-22 ホソカワミクロン株式会社 薬物含有複合粒子の製造方法および経肺製剤
JP5115951B2 (ja) * 2006-03-17 2013-01-09 学校法人東京理科大学 ナノコンポジット粒子
JP5158436B2 (ja) * 2008-09-18 2013-03-06 国立大学法人 鹿児島大学 抗菌剤およびその製造方法、化粧料ならびに医薬品
US20100183876A1 (en) * 2008-12-23 2010-07-22 Hell Andre Process for the Preparation of a Peptide Powder Form

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0317120A1 (fr) * 1987-11-12 1989-05-24 Vestar, Inc. Préparation de liposome de l'amphotéricine B
WO1991016882A1 (fr) * 1990-05-08 1991-11-14 Liposome Technology, Inc. Composition de medicament/lipides en poudre sechee par pulverisation directe
EP0655237A1 (fr) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Composition d'aerosol medicinal
WO1997026863A1 (fr) * 1996-01-24 1997-07-31 Byk Gulden Lomberg Chemische Fabrik Gmbh Procede pour fabriquer des preparations de surfactants pulmonaires en poudre
WO1997044012A1 (fr) * 1996-05-17 1997-11-27 Andaris Limited Formulation destinee a l'inhalation et comprenant des microparticules
WO1998031346A1 (fr) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation de particules pour inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0317120A1 (fr) * 1987-11-12 1989-05-24 Vestar, Inc. Préparation de liposome de l'amphotéricine B
WO1991016882A1 (fr) * 1990-05-08 1991-11-14 Liposome Technology, Inc. Composition de medicament/lipides en poudre sechee par pulverisation directe
EP0655237A1 (fr) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Composition d'aerosol medicinal
WO1997026863A1 (fr) * 1996-01-24 1997-07-31 Byk Gulden Lomberg Chemische Fabrik Gmbh Procede pour fabriquer des preparations de surfactants pulmonaires en poudre
WO1997044012A1 (fr) * 1996-05-17 1997-11-27 Andaris Limited Formulation destinee a l'inhalation et comprenant des microparticules
WO1998031346A1 (fr) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation de particules pour inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Y.-F. MAA ET AL.: "spray-drying of air-liquid interface sensitive recombinant human growth hormone", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 87, no. 2, February 1998 (1998-02-01), Washington (US), pages 152 - 159, XP000729419 *

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315983B1 (en) 1996-01-24 2001-11-13 Byk Gulden Lomberg Chemische Fabrik Gmbh Process for the production of powdered pulmonary surfactant preparations
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US7306787B2 (en) 1997-09-29 2007-12-11 Nektar Therapeutics Engineered particles and methods of use
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US6630121B1 (en) 1999-06-09 2003-10-07 The Regents Of The University Of Colorado Supercritical fluid-assisted nebulization and bubble drying
WO2001013891A3 (fr) * 1999-08-25 2001-07-26 Advanced Inhalation Res Inc Modulation de liberation a partir de formulations seches en poudre
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery
EP2851067A1 (fr) 2000-05-10 2015-03-25 Novartis AG Poudres à base de phospholipides pour l'administration de médicaments
EP1303259B1 (fr) * 2000-05-23 2013-03-20 Ethypharm Microspheres a liberation prolongee pour administration injectable et procede de preparation
RU2275900C2 (ru) * 2000-06-09 2006-05-10 Адвансд Инхалейшен Рисёч, Инк. Способ высокоэффективной доставки аэрозоля с большой терапевтической массой
US6921528B2 (en) 2000-06-09 2005-07-26 Advanced Inhalation Research, Inc. Highly efficient delivery of a large therapeutic mass aerosol
US7556798B2 (en) 2000-06-09 2009-07-07 Alkermes, Inc. Highly efficient delivery of a large therapeutic mass aerosol
WO2001095874A3 (fr) * 2000-06-09 2003-01-16 Advanced Inhalation Res Inc Distribution hautement efficace d'une grande quantite d'aerosol therapeutique
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
EP1767196A3 (fr) * 2000-06-09 2009-02-25 Advanced Inhalation Research, Inc. Libération hautement efficace d'un grand aérosol en masse thérapeutique
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US6838075B2 (en) 2000-08-07 2005-01-04 Nektar Therapeutics Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US6569406B2 (en) 2000-08-07 2003-05-27 Nektar Therapeutics Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
JP2002179589A (ja) * 2000-10-02 2002-06-26 Jcr Pharmaceuticals Co Ltd 生理活性ペプチド含有粉末
US8889180B2 (en) 2001-04-25 2014-11-18 Western University Of Health Sciences Coated drug delivery formulations
WO2002094283A3 (fr) * 2001-05-21 2003-11-27 Britannia Pharmaceuticals Ltd Utilisation de phospholipides dans le traitement de maladie degenerative du poumon et pour ameliorer l'administration de medicaments
WO2003015756A1 (fr) * 2001-08-17 2003-02-27 Upperton Limited Production de microparticules
US8936813B2 (en) 2001-11-01 2015-01-20 Novartis Ag Spray drying methods and related compositions
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US7384649B2 (en) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
JP2005511629A (ja) * 2001-11-20 2005-04-28 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続作用生成物送達用組成物
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
AU2003218306B2 (en) * 2002-03-20 2006-09-14 Advanced Inhalation Research, Inc. Method for administration of growth hormone via pulmonary delivery
AU2003218256B2 (en) * 2002-03-20 2006-07-13 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
WO2003080028A3 (fr) * 2002-03-20 2004-01-22 Advanced Inhalation Res Inc Procede et appareil de production de particules seches
US9700529B2 (en) 2002-05-03 2017-07-11 Nektar Therapeutics Particulate materials
US10945972B2 (en) 2002-05-03 2021-03-16 Nektar Therapeutics Particulate materials
US10188614B2 (en) 2002-05-03 2019-01-29 Nektar Therapeutics Particulate materials
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US9879067B2 (en) 2002-06-14 2018-01-30 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US10604560B2 (en) 2002-06-14 2020-03-31 Arexis Ab Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7294336B2 (en) 2002-06-14 2007-11-13 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US9272032B2 (en) 2002-06-14 2016-03-01 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US8986686B2 (en) 2002-06-14 2015-03-24 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US11180542B2 (en) 2002-06-14 2021-11-23 Arexis Ab Stabilized liquid anti-RSV antibody formulations
AU2003287132B2 (en) * 2002-12-13 2009-03-12 Adagit Pharmaceutical porous particles
EP1569626A1 (fr) 2002-12-13 2005-09-07 Adagit Particules pharmaceutiques poreuses
WO2004054556A1 (fr) * 2002-12-13 2004-07-01 Adagit Particules pharmaceutiques poreuses
CN100365039C (zh) * 2003-01-31 2008-01-30 日本瑞翁株式会社 可聚合组合物、热塑性树脂组合物、交联树脂以及交联树脂复合材料
US7862834B2 (en) 2003-05-28 2011-01-04 Novartis Pharma Ag Pharmaceutical formulation comprising a water-insoluble active agent
WO2005000267A3 (fr) * 2003-05-28 2005-03-10 Nektar Therapeutics Produit pharmaceutique formule comprenant un principe actif insoluble dans l'eau
AU2004251623B2 (en) * 2003-05-28 2010-03-18 Novartis Ag Spray drying of an alcoholic aqueous solution for the manufacture of a water-in-soluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
US8668934B2 (en) 2003-05-28 2014-03-11 Novartis Ag Pharmaceutical formulation comprising a water-insoluble active agent
WO2005020953A1 (fr) * 2003-08-22 2005-03-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Poudres amorphes sechees par atomisation presentant une faible humidite residuelle et une bonne stabilite au stockage
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US8710001B2 (en) 2006-07-31 2014-04-29 Novo Nordisk A/S PEGylated, extended insulins
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
US10259856B2 (en) 2008-03-18 2019-04-16 Novo Nordisk A/S Protease stabilized acylated insulin analogues
US9688737B2 (en) 2008-03-18 2017-06-27 Novo Nordisk A/S Protease stabilized acylated insulin analogues
WO2011065600A1 (fr) * 2009-11-25 2011-06-03 Gcbio Corp. Utilisation d'une formulation inhalable en poudre comprenant une hormone de croissance pour prevenir ou traiter les maladies induites par l'hypofonctionnement des recepteurs nmda
WO2013114371A1 (fr) 2012-02-01 2013-08-08 Protalix Ltd. Formulation en poudre sèche de dnase i
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
US12478640B2 (en) 2012-03-07 2025-11-25 Beyond Air Ltd Inhalation of nitric oxide for treating respiratory diseases
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
WO2014121137A2 (fr) 2013-02-01 2014-08-07 Glialogix, Inc. Compositions et méthodes utilisables en vue du traitement de maladies neurodégénératives et autres
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
WO2016057693A1 (fr) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour administration par inhalation d'oligonucléotide conjugué
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
EP3346987A1 (fr) * 2015-09-09 2018-07-18 Novartis AG Administration ciblée de formulations séchées par pulvérisation aux poumons
WO2018075865A1 (fr) 2016-10-21 2018-04-26 Glialogix, Inc. Compositions de traitement de maladies neurodégénératives
US10596231B2 (en) 2016-12-16 2020-03-24 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US10265385B2 (en) 2016-12-16 2019-04-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
WO2020223237A1 (fr) 2019-04-29 2020-11-05 Insmed Incorporated Compositions de poudre sèche de promédicaments de tréprostinil et méthodes d'utilisation de celles-ci
WO2023150747A1 (fr) 2022-02-07 2023-08-10 Insmed Incorporated Compositions de poudre sèche de bédaquiline et de sels et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
DE69936386T2 (de) 2008-03-06
JP2002523360A (ja) 2002-07-30
ES2289823T3 (es) 2008-02-01
PT1107743E (pt) 2007-10-01
ATE365547T1 (de) 2007-07-15
AU758351B2 (en) 2003-03-20
CY1107488T1 (el) 2013-03-13
EP1107743A1 (fr) 2001-06-20
AU5784299A (en) 2000-03-14
DK1107743T3 (da) 2007-10-22
JP4416325B2 (ja) 2010-02-17
CA2341624A1 (fr) 2000-03-02
DE69936386D1 (de) 2007-08-09
EP1107743B1 (fr) 2007-06-27
CA2341624C (fr) 2008-12-02

Similar Documents

Publication Publication Date Title
CA2341624C (fr) Formulations proteiques atomisees stables
US6956021B1 (en) Stable spray-dried protein formulations
US6586008B1 (en) Use of simple amino acids to form porous particles during spray drying
US7807200B2 (en) Formulations for spray-drying large porous particles
US5855913A (en) Particles incorporating surfactants for pulmonary drug delivery
EP1210069B1 (fr) Grandes particules poreuses susceptibles d'etre obtenues par le sechage par atomisation et aptes a l'administration pulmonaire
US7678364B2 (en) Particles for inhalation having sustained release properties
US20030068277A1 (en) Particles for inhalation having sustained release properties
US7252840B1 (en) Use of simple amino acids to form porous particles
HK1101138A (en) Stable spray-dried protein formulations
EP1767195A2 (fr) Formulations de protéines stables séchées par pulvérisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 57842/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2341624

Country of ref document: CA

Ref country code: CA

Ref document number: 2341624

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999945175

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999945175

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 57842/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999945175

Country of ref document: EP